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Abstract
Mitochondria are highly integrated organelles that are crucial to cell adaptation and
mitigating adverse physiology. Recent studies demonstrate that fundamental signal
transduction pathways incorporate mitochondrial substrates into their biological pro‐
grams. Reversible phosphorylation is emerging as a useful mechanism to modulate
mitochondrial function in accordance with cellular changes. Critical serine/threonine
protein kinases, such as the c‐Jun N‐terminal kinase (JNK), protein kinase A (PKA),
PTEN‐induced kinase‐1 (PINK1), and AMP‐dependent protein kinase (AMPK), readily
translocate to the outer mitochondrial membrane (OMM), the interface of mitochon‐
dria‐cell communication. OMM protein kinases phosphorylate diverse mitochondrial
substrates that have discrete effects on organelle dynamics, protein import, respira‐
tory complex activity, antioxidant capacity, and apoptosis. OMM phosphorylation
events can be tempered through the actions of local protein phosphatases, such as
mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) and protein phosphatase
2A (PP2A), to regulate the extent and duration of signaling. The central mediators of
OMM signal transduction are the scaffold proteins because the relative abundance of
these accessory proteins determines the magnitude and duration of a signaling event
on the mitochondrial surface, which dictates the biological outcome of a local signal
transduction pathway. The concentrations of scaffold proteins, such as A‐kinase an‐
choring proteins (AKAPs) and Sab (or SH3 binding protein 5—SH3BP5), have been
shown to influence neuronal survival and vulnerability, respectively, in models of
Parkinson's disease (PD), highlighting the importance of OMM signaling to health and
disease. Despite recent progress, much remains to be discovered concerning the
mechanisms of OMM signaling. Nonetheless, enhancing beneficial OMM signaling
events and inhibiting detrimental protein‐protein interactions on the mitochondrial
surface may represent highly selective approaches to restore mitochondrial health
and homeostasis and mitigate organelle dysfunction in conditions such as PD.
KEYWORDS

A-kinase anchoring protien, c-Jun N-terminal Kinase (JNK), leucine-rich repeat kinase 2
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1 | BAC KG RO U N D

dynamics, organelle function, and apoptosis demonstrating the im‐
portance of coordinated mitochondria‐cell communication.

Mitochondria are highly integrated organelles responsible for reg‐

The outer mitochondrial membrane (OMM) is the interface be‐

ulating cellular bioenergetics and viability in a continually changing

tween mitochondria and the rest of the cell. Despite that most mito‐

environment. This extensive level of integration requires intricate

chondrial proteins reside within the inner mitochondrial membrane

and precise systems for communication with other cellular com‐

(IMM), the OMM hosts significant elements of mitochondrial phys‐

partments. As the cellular environment changes, mitochondria

iology including organelle dynamics, protein import, and apoptosis.

must adjust their function, and cells must be able to detect, re‐

Consequently, protein kinases and phosphatases on the OMM are

spond, and modulate mitochondria rapidly to adapt. Mitochondria

appropriately positioned to convey signals to and from mitochon‐

have evolved sophisticated signaling mechanisms with cells that

dria to directly manipulate mitochondrial form and function. The

involve gases, ions, hormones, metabolites, and proteins.1 Thus,

importance of OMM signaling is supported by numerous studies

mitochondria are crucial hubs for receiving, integrating, and trans‐
2

mitting signals within cells. Environmental, cellular, and organelle‐

demonstrating that cytosolic kinases migrate to the organelle sur‐
face and modify local substrates to affect mitochondrial physiol‐

based messengers impact all areas of mitochondrial physiology

ogy.8,9,11 Neurons have a particular reliance on mitochondria for

including genome integrity, bioenergetics, translation, and protein

energy production, calcium buffering, and managing ionic changes

import (Figure 1).

3

related to synaptic transmission.12 Furthermore, dysfunction of

The quickness necessitated for accurately adjusting mitochon‐

OMM signaling components can contribute to the pathophysiology

drial function to physiological perturbations implies that post‐trans‐

of neurodegenerative diseases, such as Alzheimer's disease (AD) and

lational modifications (PTMs) of local proteins are used before the

Parkinson's disease (PD).9,13

induction of transcriptional programs. Reversible phosphorylation

In this review, we will identify the kinases and phosphatases found

has emerged as a prominent mechanism for rapidly regulating mi‐

on the OMM (summarized in Table 1) of neurons and other CNS cells.

tochondrial protein function; in fact, recent proteomic studies in‐

We will present the molecular architecture required for each signaling

dicate that ~40% of the organelle proteome is phosphorylated.4-8

protein and discuss the effects of specific substrate phosphorylation

Additionally, over 30 protein kinases and phosphatases are reported

events including the impacts on organelle and neuronal physiology.

6,8-11

We will highlight how perturbations in kinase and phosphatase activ‐

to migrate to mitochondria or have mitochondrial substrates.

These phosphorylation events affect metabolism, mitochondrial

ities can contribute to the pathophysiology of neurological diseases.

F I G U R E 1 Mitochondrial signaling mechanisms regulate organelle, cell, and organisms physiology. Mitochondria are influenced by the
intracellular and extracellular stimuli such as ions, metabolites, and molecules in the environment like oxygen and pesticides. However, the
impact of signaling cascades in response to indirect actions of second messengers or stressors is emerging as significant manipulators of
physiology. Mitochondrial signaling and second messengers have been shown to affect mitochondrial processes ranging from local events
such as bioenergetics, mitochondrial dynamics, and proteins import to controlling transcriptional programs such as mitochondrial biogenesis,
gene expression, and redox homeostasis. Of course, mitochondria are crucial to cell viability because the organelles are home to cell death
machinery. Mitochondrial signaling can also transcend the cell through metabolites, second messengers, and even extracellular vesicles to
impact metabolism, immune responses, inter‐tissue signaling, and the microbiota within an organism. Mitochondrial signaling has emerged
as a critical component to human health and disease. The stimuli and transcriptional programs converge on signaling proteins on the outer
mitochondrial membrane (OMM), which are uniquely positioned to receive and convey signals from both cell and organelle. Discrete OMM
signaling events then coordinate mitochondrial and cellular responses to adapt organelle, cell, and organismal physiology to the current
environment

|
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TA B L E 1
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Summary of select mitochondrial substrates of OMM kinases and phosphatases
Proposed
substrates

Amino acid

Inhibit/activate

Pathway/activity

Suppress/
promote

Identified on OMM

Ref.

AMPK

MFF
AKAP‐1

Ser172
Ser103

Activate
Activate

Fission
Signaling

Promote
Promote

Colocalization
Phosphoproteomics

266

Cdk1

Drp‐1

Ser616

Activate

Fission

Promote

Colocalization

195

Ser616

Activate

Fission

Promote

Protein
Kinase

Cdk5

Drp‐1

Cdk11

Unknown

CKI

Bid

Ser64/66

Inhibit

Apoptosis

CK2

Bcl‐2 proteins
FUNDC1
MIM1/2
TOM20
TOM22

Ser13
Ser12/16
Ser172
Ser44/46

Inhibit
Inhibit
Inhibit
Inhibit
Inhibit

Bcl‐2 proteins
Drp‐1
Mfn1
PGK‐1
StAR
TRAP1

Ser616
Thr562
Ser203
Ser232
Ser511/568

Bcl‐2 proteins
Mfn2
PDH‐Eα1
SH3BP5
Smac/DIABLO
smARF2

120

Colocalization
Colocalization

203

Suppress

Colocalization

207

Apoptosis
Mitophagy
Protein import
Protein import
Protein import

Suppress
Suppress
Suppress
Suppress
Suppress

Colocalization

207

Inh/Act
Activate
Inhibit
Activate
Activate
Activate

Apoptosis
Fission
Fusion
Metabolism
Metabolism
Metabolism

Supp/Prom
Promote
Suppress
Suppress
Promote
Suppress

Colocalization

Ser27
TBD
Ser421
Ser6
TBD

Inh/Act
Inhibit
Inhibit
Activate
Activate
Activate

Apoptosis
Fusion
Metabolism
Signaling
Apoptosis
Mitophagy

Supp/Prom
Suppress
Suppress
Promote
Promote
Promote

Colocalization

Bcl‐2
Miro
MCU
PRDX3

Thr56
TBD
TBD
Thr146

Activate
Inhibit
Activate
Inhibit

Autophagy
Trafficking
Ca2+ Transit
Antioxidant

Promote
Suppress
Promote
Suppress

Colocalization

mTOR

Bcl‐xL

Ser62

Activate

Glycolysis

Promote

Colocalization

216

PAK5

Bad

Ser112

Inhibit

Survival

Suppress

Colocalization

223

PINK1

AKAP‐1
Parkin
PINK1
Ub

TBD
Ser65
Ser228/402
Ser65

Inhibit
Activate
Activate
Activate

Signaling
Mitophagy
Mitophagy
Mitophagy

Suppress
Promote
Promote
Promote

Colocalization
Proteomics

178

AIF1
Bad
Bax
Bim
Drp1
GSTA4‐4
MIC19
MIC60
NDUFS4
TOM22
TOM40
TOM70
VDAC1

Ser39
Ser112/155
Ser60
Ser83
Ser637
Ser189
Thr11
Ser528
Ser173
Thr76
Ser54
Ser174
TBD

Inhibit
Inhibit
Inhibit
Inhibit
Inhibit
Activate
Inhibit
Inhibit
Activate
Inhibit
Inhibit
Inhibit
Inhibit

Bioenergetics
Apoptosis
Apoptosis
Apoptosis
Fission
Antioxidant
MICOS/Mitophagy
MICOS/Mitophagy
Bioenergetics
Protein Import
Protein Import
Protein Import
Ion Homeostasis

Promote
Suppress
Suppress
Suppress
Suppress
Promote
Suppress
Suppress
Promote
Suppress
Suppress
Suppress
Suppress

Colocalization
Proteomics

PKC

Drp‐1
ECE‐1

Ser616
TBD

Activate
Activate

Fission
Amyloid Clearance

Promote
Promote

Colocalization

149

P38γ

Bcl‐2 proteins
Sab (SH3BP5)

TBD

Inh/Act
Activate

Apoptosis
Signaling

Supp/Prom
Promote

Colocalization

81

ERK1/2

JNK

LRRK2

PKA

Apoptosis

210
123

62
75
76
77
80
78
34
57
52,53
28
47
56
159
164
165
166

179
173
175
131
95
129
130
121
105
105
110
124
125
126
267

152

86

(Continues)
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TA B L E 1

(Continued)
Proposed
substrates

Amino acid

Inhibit/activate

Pathway/activity

Suppress/
promote

MKP‐1

JNK
MAPKs

Thr183/
Tyr185

Inhibit
Inhibit

Apoptosis
ROS production

PP1

AKAP1
Bad
Bcl‐2
P38

TBD
Ser112/136
Ser70
Thr180/
Tyr182

Activate
Activate
Inhibit
Inhibit

Bad
Bcl‐2
Drp1

Ser112
Ser70
Ser656

PTEN‐L

Parkin
Ubiquitin

PTP1D

AKAP1
Src

Protein

Identified on OMM

Ref.

Suppress
Suppress

Colocalization

224

Signaling
Apoptosis
Apoptosis
Signaling

Promote
Promote
Suppress
Suppress

Colocalization

248

Activate
Inhibit
Activate

Apoptosis
Apoptosis
Fission

Promote
Promote
Promote

Colocalization
Proteomics

238

Ser65
Ser65

Inhibit

Mitophagy

Suppress

Colocalization

229

TBD
Tyr530

Activate
Activate

Signaling
Bioenergetics

Promote
Promote

Colocalization

239

Phosphatase

PP2A

2 | O M M PROTE I N K I N A S E S

236
230
231

237
95

JNK substrates and physiological roles of JNK signaling in the
brain with nuclear and cytosolic isoforms targeting different sub‐

Protein kinases influence mitochondrial protein function through

strate pools. The cytosolic JNK species probably become the mi‐

phosphorylation. Intriguingly, most kinase activity within mito‐

tochondrial JNK species based on localization. Also, the functional

chondria can be attributed to tyrosine kinases such as Src.14,15

redundancy and compensatory activities of JNK isoforms indicate

Alternatively, much of the phosphorylation on the mitochondrial

that multiple JNKs could contribute to mitochondrial JNK signal‐

surface is associated with serine/threonine (Ser/Thr) protein ki‐

ing.18,21,22 In cerebral ischemia, researchers propose that JNK1

nases.8 Accordingly, the OMM protein kinases are almost exclusively

may be an early mitochondrial effector with JNK3 migrating to mi‐

Ser/Thr kinases, which we will discuss below.

tochondria later and inducing apoptosis. 23 Similarly, in 1‐methyl‐4‐
phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced dopaminergic

3 | M ITO G E N ‐AC TI VATE D PROTE I N
K I N A S E S (M A PK S)

(DA) neuron degeneration in mice, ablation of both JNK2 and
JNK3 was necessary to protect DA neurons from the neurotoxic
insult. 24,25 These data imply that JNK1 is involved in physiological
JNK signaling, while JNK2 and JNK3 are responsible for JNK‐me‐

MAPKs, namely the c‐Jun N‐terminal kinase (JNK), extracellular regu‐

diated apoptosis; meanwhile, these studies highlight the potential

lated kinase (ERK1/2), and p38,16 exhibit transient mitochondrial locali‐

for all JNK isoforms to localize on mitochondria.

zation in responses to cellular stimuli and stress. The principal targets

Mitochondrial JNK signaling is linked to apoptosis in numerous

of mitochondrial MAPKs appear to be the Bcl‐2 protein superfamily

tissues, including the brain, following cytotoxic stress. While the

members, which explains the impact mitochondrial MAPKs have on

molecular mechanism of JNK translocation to the OMM remains to

the regulation of cell death pathways.16 Recent studies show that JNK,

be determined, the scaffold protein, Sab (or SH3BP5), anchors JNK

ERK, and p38 can phosphorylate OMM substrates involved in mito‐

on mitochondria. 26-28 Sab is a single‐pass transmembrane protein

chondrial dynamics and bioenergetics.

oriented in the OMM with the N terminus of the protein in the mito‐
chondrial intermembrane space and the C terminus on the cytosolic

3.1 | c‐Jun N‐terminal kinase
The most well‐characterized MAPK with OMM localization is
the c‐Jun N‐terminal kinase (JNK). There are three JNK isoforms

face of the OMM. 29 JNK interacts with Sab through kinase interact‐
ing motifs (KIM1/2) near the C terminus of Sab, 26,28,30 and ablation
of these sites or use of a competitive peptide (Tat‐SabKIM1) can pre‐

vent JNK translocation to mitochondria. 26,31,32 Disrupting the inter‐

(JNK1, JNK2, and JNK3) that are expressed in the brain, and stud‐

action between JNK and Sab is neuroprotective in rodent models of

ies from mice suggest that JNK isoforms account for most of the

PD and cerebral ischemia. 23,33

proline‐directed phosphorylation in the brain.17,18 The activities of

Mitochondrial JNK activity impacts apoptosis, metabolism, and

JNKs have been delineated in rodent brains with JNK1 account‐

organelle dynamics (Figure 2); perhaps, the most widely identified

ing for most of the signaling in the cortex and cerebellum, and

JNK mitochondrial substrates are proteins from the Bcl‐2 superfam‐

JNK3 accounts for the bulk of activity in the hippocampus and

ily.34 JNK phosphorylates many members of the Bcl‐2 superfamily

19,20

striatum.

Discrete subcellular may contribute to the diverse

to modulate their functions in stress, tissue, and cell‐dependent

|
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fashion. Concerning Bcl‐2 proteins in the CNS, JNK directly modifies

841

intermembrane components, is a potential JNK substrate. Putative

Bcl‐2, Bad, and Bim and induces expression of apoptotic proteins,

JNK phosphorylation of Smac/DIABLO mediates the release from

like activator of apoptosis Harakiri (HRK) to promote cell death in

mitochondria to ubiquitinylate inhibitors of apoptosis (IAPs) for

response to neurotoxic stress.35-37 Our research demonstrated that

degradation and sustains apoptosis.46-48 In addition to modifying

mitochondrial JNK could phosphorylate Bcl‐2 on Ser70 to induce

mitochondrial resident Bcl‐2 superfamily proteins, JNK acts perimito‐

emigration of Bcl‐2 from the OMM, in response to 6‐hydroxydopa‐

chondrially in the cytoplasm to induce translocation of proteins such

mine exposure in vitro and in vivo. 26,33 The loss of Bcl‐2 from the

as Bad and Bax to mitochondria. This is achieved either by directly

mitochondrial surface releases BH3‐only proteins and Bax to engage

phosphorylating the proteins or by phosphorylation of their cytosolic

in mitochondrial outer membrane permeabilization (MOMP) initiat‐

scaffold, 14‐3‐3, to induce their release.49-51 Consequently, local JNK

ing apoptosis.38,39 Similarly, inhibition of pro‐survival OMM‐resident

signaling on the OMM is a crucial component of neuronal apoptosis.

Mcl‐1 by JNK on Thr163 and Ser121 has been shown to promote

In addition to regulating cell viability, JNK signaling is associated

apoptosis.40,41 The inactivation of Mcl‐1 by JNK is an event impli‐

with bioenergetics in the brain. The first evidence of the regulation

cated in neurotoxic degenerative models 42 as well as elevated JNK

of mitochondrial metabolism by local JNK signaling came from stud‐

reveals

ies in the aging mouse brain.52,53 JNK was found to phosphorylate

the importance of mitochondrial JNK inhibition of pro‐survival pro‐

pyruvate dehydrogenase (PDH) complex on the E1α subunit and

teins in CNS disorders.

impaired PDH activity. 52,53 JNK‐mediated inhibition of PDH leads

activity in postmortem neurodegenerative brain tissue

43,44

Alternatively, JNK has been shown to phosphorylate Bim on

to increase lactic acid levels and perhaps contributing to energetic

Ser65 during trophic factor deprivation (TFD) as part of apoptosis

deficits in the aging brain. Our research and studies in the liver by

initiation. Again, JNK phosphorylation of Bim facilitated MOMP in

Win and colleagues

Bax‐dependent apoptosis.

35,37

26,29,54,55

demonstrate that JNK can impair the

Other BH3‐only proteins have been

activity of respiratory complex I. Although the precise mechanism

documented as JNK substrates, including Bad, Bid, and Noxa.34 JNK

has yet to be determined, JNK translocation to the OMM is linked

directly phosphorylates Bax on Thr167 to promote oligomerization

to enhanced ROS production. The direct inhibition of both PDH

and pore formation in the OMM leading to the release of apoptotic

and complex I by JNK is problematic given that the substrates are

contents of the intermembrane space.45 Smac/DIABLO, one of these

within the mitochondria, and JNK had been shown to be present

F I G U R E 2 c‐Jun N‐terminal kinase (JNK) on the OMM impacts apoptosis and bioenergetics. JNK signaling has long been linked to cell
death and metabolism, and only recently was it realized that mitochondrial JNK signaling on the OMM scaffold protein Sab was critical
to the induction of apoptosis through the manipulation of proteins within the Bcl‐2 superfamily. Following activation, JNK translocates
to mitochondria. JNK interacts with and phosphorylates the OMM scaffold protein Sab most likely through an interaction with the KIM2
motif (K2) because the KIM1 motif (K1) may be on the inner leaf of the OMM. In cases of neurotoxin exposure, ischemia, and cytotoxic
stress, mitochondrial JNK activity leads to amplification of ROS production, organelle dysfunction, and cell death. Mitochondrial JNK can
impair complex I by a yet‐to‐be‐described mechanism to impair mitochondrial metabolism and engage ROS production. However, this
may be facilitated by signaling on the coiled‐coil motifs (CC1/CC2) of Sab's SH3 domain. Mitochondrial JNK can initiate apoptosis through
phosphorylation of Bcl‐2 on Ser70 inducing its emigration from mitochondria. JNK activity on mitochondria has also been demonstrated
to impact mitochondrial dynamics through phosphorylation of Mfn2, which leads to its degradation and mitochondrial fission. JNK also
influences mitochondrial metabolism directly through the inhibition of PDH via phosphorylation of the Eα1 subunit. In addition to Bcl‐2,
JNK can also influence the activities of BH3‐only proteins such as Bim to induce apoptosis, and mitochondrial JNK has been shown to
phosphorylate Bax to induce permeabilization of the OMM. The local activities of mitochondrial JNK suggest it could be a significant
physiological player in organelle health

842
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on the mitochondrial surface. Therefore, JNK phosphorylates the

ER stress‐induced apoptosis.65 Intriguingly, HSPB1 mutations from

substrates either before or during protein import, unless indirect

Charcot‐Marie‐Tooth disease exhibit high levels of BIM and are more

mechanisms may be responsible for the inhibition. This appears

vulnerable to ER stress‐induced cell death than their wild‐type coun‐

to be the case for complex I, as Win and associates found that in‐

terparts.65 However, ERK1/2 phosphorylation of Bcl‐2 and Mcl‐1

Upon JNK

has been described to have conflicting effects in the literature.66 For

binding/phosphorylation of Sab, Src inhibitor SHP‐1, a tyrosine

example, ERK1/2 phosphorylation of Bcl‐2 can prevent Bcl‐2 func‐

phosphatase, is responsible for dephosphorylating Src Tyr419 inac‐

tion activating neuronal apoptosis

hibitors of intramitochondrial Src associate with Sab.

tivating the kinase and reducing complex I activity.

29

29

67-70

; meanwhile, other reports

These studies

indicate that ERK1/2 phosphorylation of Bcl‐2 promotes the pro‐

implicate mitochondrial JNK as a crucial metabolic regulator and

tein's anti‐apoptotic activities.71-73 Similar studies have been noted

illustrate the possibility of transmembrane signaling cascades at

for Mcl‐1 with ERK1/2 phosphorylation both inhibiting and enhanc‐

mitochondria, which may serve as intra‐ and extra‐organelle com‐

ing Mcl‐1 anti‐apoptotic functions.74 Thus, considerable attention

munication circuits.

should be paid to the cellular and stress contexts of ERK1/2 signal‐

Recently, JNK signaling has been linked to mitochondrial dy‐
namics and quality control through the phosphorylation of OMM

ing when examining Bcl‐2 phosphorylation especially in the diverse
cellular populations of the CNS.

substrates,56,57 and although this work was not performed in the

ERK1/2 activity has also been implicated as a regulator of mi‐

CNS, the implications of impaired mitophagy and JNK signaling in

tochondrial dynamics. Mitochondrial ERK2 translocation emulates

neurodegenerative disorders warrant the mention of this relation‐

6‐OHDA‐mediated effects on mitophagy.61 Additionally, mitochon‐

ship. 24,43,58,59 Specifically, JNK2 was found to translocate to mito‐

drially localized ERK1/2 can phosphorylate dynamin‐related pro‐

chondria and phosphorylate the mitochondrial form of the alternate

tein 1 (Drp‐1) and Mfn1 to impair fusion. It was reported in 2015

reading frame tumor suppressor [ARF (smARF, small ARF)] leading

by two independent studies that ERK2 could phosphorylate Drp‐1

to ubiquitination and degradation by the proteasome.56 Diminished

on Ser616 and promote mitochondrial fission.75 This event was

smARF levels raised the steady‐state levels of p62, a mediator of au‐

shown to be driven by the Ras oncogene and necessary for tumor

tophagic‐lysosomal degradation, which was more readily degraded

growth. ERK2‐Drp‐1 activation was later revealed to be required

in the absence of JNK2.56 Ablation of JNK2 produced higher levels

for cellular programming during development.75 Also, in 2015,

of basal mitophagy and autophagy and was typified by high smARF

Pyakural and colleagues demonstrated that ERK1/2 phosphoryla‐

and low p62 (a result of increased autophagy) levels.

56

Mitochondrial

tion of Mfn1 on Thr562 impaired the organelle docking activities

JNK activity has also been linked to the turnover of mitofusin‐2

of Mfn1.76 Expression of constitutively active MAPK/ERK kinase

(Mfn2) but not Mfn1. JNK was shown to phosphorylate Mfn2 on

(MEK) resulted in mitochondrial fragmentation. Also, ERK1/2 phos‐

Ser27, which promoted the ubiquitination and proteasomal degrada‐

phorylation of Mfn1 also sensitized cells to apoptotic stimuli impli‐

tion of Mfn2.

57

The loss of Mfn2 contributed to mitochondrial frag‐

cating mitochondrial ERK signaling in both functional and cell death
responses.76

mentation in human U2OS osteosarcoma cells.
Additionally, the loss of Mfn2 was associated with induction of

ERK1/2 signaling can impact bioenergetics and mitochondrial

apoptosis to genotoxic stress induced by doxorubicin.57 Therefore,

metabolism as well. Recent reports have suggested that ERK1/2 is

it is possible that local JNK signaling can contribute to the turnover

necessary to induce glycolysis. One proposed mechanism for ERK

of stressed mitochondria by enhancing fission and degradation of

regulation of glycolysis involves the phosphorylation of phospho‐

problematic organelles. Collectively, mitochondrial JNK is a crucial

glycerate kinase 1 (PGK‐1) by ERK1/2 on Ser 203.77 This phosphor‐

regulator of mitochondrial form and function as well as cellular via‐

ylation event induces mitochondrial PGK‐1 to become a protein

bility in the CNS.

kinase that phosphorylates and activates PDH kinase 1 (PDHK1)
on Thr338. PDHK1, in turn, phosphorylates PDH inhibiting en‐
zyme activity and promoting glycolysis.77 Another recent report

3.2 | Extracellular regulated kinase

demonstrates that in the presence of mutations in neurofibromin,

The extracellular regulated kinase (ERK) exists as numerous isoforms

a hallmark of neurofibromatosis type 1 (a condition that predis‐

in the brain with ERK1/2 being the most well‐characterized species

poses patients to tumor formation), ERK1/2 phosphorylates the

of the family. Similar to JNK, ERK1/2 activity on the mitochondria

chaperone TRAP1.78 Phosphorylation of TRAP1 impairs succinate

has been reported in the hippocampus,

60

and is

dehydrogenase (SDH) leading to the accumulation of succinate and

associated with the post‐translational modification of Bcl‐2 family

tumor progression.78 The most widely recognized metabolic inter‐

members

62

and organelle physiology.

implicated in PD,

61

63,64

Although ERK1/2 activ‐

action is between ERK1/2 and the steroidogenic acute regulatory

ity generally is thought to be pro‐survival, prolonged ERK1/2 signal‐

protein (StAR).79 ERK1/2 phosphorylates StAR on Ser 232, which

ing can be linked to cell death as well.

62

ERK1/2 signaling outcomes

stabilizes the protein in mitochondria and sustains steroid synthesis.

are stimulus‐ and cell‐type‐dependent, as is the case with most

ERK activity, along with protein kinase A (PKA), is required for max‐

MAPKs. Recently, ERK1/2 interaction with heat shock protein B1

imal steroid production in Leydig cells.80 These studies collectively

(HSPB1) was shown to facilitate the phosphorylation of the BH3‐

implicate local ERK signaling in the regulation of mitochondrial form

only protein Bim leading to its degradation and ultimately impairing

and function.

|
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mitochondrial PKA through genetic and pharmacological manipu‐

3.3 | P38 kinases

lation has been shown to be neuroprotective in preclinical models

The p38 kinases, in particular p38α (MAPK14), have been implicated

of neurodegenerative diseases, specifically PD.95-97 Furthermore,

in the pathogenesis of neurodegenerative, and pharmacological in‐

adding an OMM localization signaling to the N terminus of PKA can

hibitors of p38 have been shown to protect against neuronal loss in

diminish the effects of mitochondrial toxins and stress.95,96 These

preclinical models of neurodegenerative disorders in the CNS.81,82

protective effects are best represented by the mitochondrial sub‐

The basis for these studies stems from the involvement of p38 in

strates of PKA on the OMM described immediately below and in

apoptosis. The general effect of p38 signaling affects the levels of

Figure 3.

Bcl‐2 (decrease) and Bax (increase) levels on mitochondria through

The most recent analysis of PKA with concerning OMM sig‐

transcriptional and post‐transcriptional means contributing to po‐

naling and organelle physiology have involved the molecular ma‐

tentiating cells toward apoptosis.83 However, p38 direct effects on

chinery of mitochondrial dynamics.98 Mitochondrial PKA was first

Bcl‐2 superfamily proteins remain elusive. Nonetheless, p38 has

linked to organelle dynamics through phosphorylation of Drp‐1.99

been shown to migrate to mitochondria follow stress (such as is‐

PKA phosphorylation of Drp‐1 on Ser637 impairs the function of

chemia or oxidative stress) in cardiac tissue.

84

Court and colleagues

Drp‐1 preventing fission, which results in elongated mitochondria.

proposed that p38γ interacts with outer mitochondrial protein 25

Ablation of Drp‐1 Ser637 or dephosphorylation by calcineurin

(OMP25) that impaired p38γ activity in vitro.85 To date, mitochon‐

was found to activate Drp‐1 leading to organelle fragmentation.99

drial p38, specifically p38γ, has been shown to converge on mito‐

Increasing mitochondrial PKA was found to also protect neurons

chondria and phosphorylate Sab, a well‐established mitochondrial

from neurotoxin‐induced cell death in part through phosphorylation

scaffold protein for JNK.86 Investigators demonstrated in vitro p38γ

of Drp‐1.95 The manipulation of Drp‐1 by PKA could be crucial to

phosphorylated Sab on Ser321,

86

which is in KIM1, preceding a

maintaining mitochondrial integrity and health and may affect mito‐

transmembrane motif. 29 This places Ser321 within the mitochondria,

chondrial transport in neurons as well as mitochondrial integration

and no documentation of p38 within mitochondria has been made

at synapses.96,100-103

raising questions to the contributions of this PTM to physiological

PKA activity on the OMM has been shown to influence the sta‐

mitochondrial signaling. Regardless, p38 is a significant player in

bility of PTEN‐induced kinase‐1 (PINK1),104 which is a crucial com‐

signaling regulating mitochondrial health.

ponent of mitophagy, through the phosphorylation of proteins in the
mitochondrial contact site and cristae organizing system (MICOS).105
Increasing PKA mitochondrial activity was found to prevent Parkin

4 | PROTE I N K I N A S E A , G , C ( AG C
K I N A S E S)

els. Investigators determined that PKA phosphorylation of MIC60,

The AGC kinase family has two members present on the OMM that

an unknown mechanism leading to its degradation.105 Meanwhile,

can influence organelle physiology: PKA and isoforms of PKC. 87

mitochondrial PKA phosphorylation of MIC19 on Thr11 was found

PKA is likely the most well‐investigated cytosolic kinase on the

to impair Parkin recruitment to mitochondria. Also, elevating the

recruitment to depolarized mitochondria by decreasing PINK1 lev‐
a MICOS component, on Ser528 destabilized PINK1 in the OMM by

mitochondrial surface, as it is well documented to play a role in

levels of PKA on mitochondria reduced the amount of organelle de‐

sustaining organelle health. 88 Meanwhile, the role of PKC on mito‐

polarization in cultures.105 While these results indicate that PKA is

chondria is more complicated with distinct variants contributing to

involved in the regulation of mitophagy, it is exciting to think that

the divergent aspects and outcomes of mitochondrial function and

coregulation of energetic and communication components of in

health.

89,90

MICOS can be manipulated by signal transduction pathways to in‐
fluence organelle turnover and health. Perhaps, this interplay may

4.1 | Protein kinase A (PKA)

represent a new therapeutic avenue for the treatment of neurode‐
generative disorders, such as PD.97,104

Mitochondrial PKA has long been associated with mitochondria

Mitochondrial PKA has been long associated with respiratory

through its interaction with scaffold proteins of the A‐kinase an‐

function and efficiency of complexes in the ETC through the manip‐

choring proteins (AKAP) family in particularly AKAP‐1 (or D‐AKAP

ulation of protein import and the direct phosphorylation of protein

as often used for the mitochondrial PKA scaffold).91,92 PKA has

subunits of respiratory enzyme systems.106-109 Mitochondrial PKA

been documented to affect numerous mitochondrial proteins rang‐

has been shown to directly affect the functions of ETC complexes

ing from bioenergetics to dynamics to redox homeostasis and cell

I, IV, and V to promote respiration and ATP synthesis.106-108 A com‐

survival.93 The substrates for mitochondrial PKA have been iden‐

plex I target of PKA is NADH:ubiquinone oxidoreductase subunit

tified both on and within mitochondria suggesting the ability of

S4 (NDUFS4). PKA phosphorylation of NDUFS4 on Ser173 pro‐

mitochondrial PKA to transcend the OMM. Mitochondrial PKA

motes interaction with the Hsp70 chaperone facilitating NDUFS4

signaling is thought to be mainly beneficial to the organelle facili‐

import into mitochondria and integration with other complex I sub‐

tating essential functions such as protein import while impeding

units.110 Consequently, mutations that disrupt the NDUFS4 Ser173

processes such as fission and apoptosis.94 Increasing the levels of

phosphorylation site are linked to complex I dysfunction in the
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F I G U R E 3 Mitochondrial PKA is a central mediator of mitochondrial health. PKA is a well‐documented regulator of mitochondrial form
and function. The actions of PKA can be inhibitory to local processes or activate others. PKA interacts with AKAP1 (D‐AKAP) on the
mitochondrial surface. PKA OMM activity can phosphorylate and impair the activity of Drp‐1 preventing fission and resulting in elongating
mitochondria. Similarly, mitochondrial PKA activation of MIC60 can influence PINK1 stability on the OMM. Phosphorylation of MIC60
leads to the decline in PINK1 levels and prevent Parkin recruitment. This could be a potential mechanism for PKA to protect healthy
mitochondria. Mitochondrial PKA can phosphorylate and inhibit the apoptotic actions of Bad. Alternatively, PKA can increase the function
of mitochondrial proteins. Mitochondrial PKA can also phosphorylate VDAC and contribute to stress‐induced mitochondrial depolarization.
Alternatively, PKA phosphorylation of OMM transporters such as TOM22 facilitates the import of nuclear‐encoded proteins (IE, subunits of
the respiratory chain). PKA phosphorylation can coincide with protein import, as in the case of NDUFS4, a complex I subunit can enhance
protein function and the efficiency of ETC complexes. These studies indicate mitochondrial PKA is required for healthy mitochondria
mitochondrial encephalomyopathy Leigh syndrome, a neuromuscu‐

D‐AKAP to engage ATP production and promote cell survival.120

111,112

lar disorder associated with impaired mitochondria function.

Mitochondrial PKA can be considered to be a crucial component of

In addition to modification of NDUFS4, mitochondrial PKA also in‐

ETC and mitochondrial bioenergetic regulation.

fluences the protein stability of complex I by inhibiting intramito‐

Mitochondrial PKA is an embedded regulator of mitochondrial

chondrial proteases capable of degrading complex I constituents,

antioxidant capacity. Mitochondrial PKA can phosphorylate a glu‐

NDUFA9, NDUFS4, and NDUFV2.113

tathione S‐transferase variant (GSTA4‐4) on Ser189.121 Similar to

Pharmacological inhibition of mitochondrial soluble adenylyl cy‐

NDUFS4, PKA phosphorylation of GSTA4‐4 facilitates its interac‐

clase (sAC) results in the proteolytic degradation of these compo‐

tion with Hsp70 and subsequent import into mitochondria.121 This

nents due to diminished local PKA activity.113 Alternatively, complex

event enhances glutathione production in mitochondria and in‐

IV (cytochrome c oxidase) subunits can be directly phosphorylated

creases antioxidant capacity within organelles.

by mitochondrial PKA, and distinct modifications can serve to mod‐

While mitochondrial PKA activity can increase the import of

ulate complex function.114 For example, PKA phosphorylation of

proteins by promoting interactions with chaperones like Hsp70,

complex IV subunit I on Ser58 nullifies ATP‐dependent inhibition

local PKA activity can phosphorylate protein transporters on the

of complex IV sustaining activity, whereas PKA phosphorylation of

mitochondrial surface and impede their functions.122,123 PKA phos‐

subunits I, IV‐1, and Vb during hypoxia triggers degradation of the

phorylation of TOM22 on Thr76124 and TOM40 on Ser54125 can

115,116

proteins and diminishes complex IV activity.

prevent transport of the proteins into mitochondria; additionally,

Similarly, mitochondrial PKA can modulate complex V activity.

the PKA phosphorylation of TOM22 can also impair its transport

Local PKA phosphorylation of ATPase inhibitory factor 1 (AIF1) on

functions.124 Similarly, PKA can phosphorylate TOM70 on Ser174,

Ser39 prevents the interaction between AIF1 and complex V main‐

which inhibits TOM70 receptor‐type activities toward chaperone

taining ATP synthase activity.117,118 Also, decreasing PKA activity in

functions such as Hsp70.126 To reconcile the distinctions between

mitochondria can lead to the proteolytic degradation of complex V

PKA's facilitation and inhibition of protein import into mitochondria,

components resulting in less ATP synthesis.118,119 The proximity of

the levels, and duration as well as the context of PKA, as well as

PKA to the bioenergetic machinery makes the kinase a useful regu‐

other signaling events, should be taken into account when observing

lator of ATP production and the ETC Furthermore, the relationship

mitochondrial outcomes.

between ATP production and mitochondrial PKA activity extends to

Finally, PKA signaling on mitochondria was found to impair

signaling transduction pathways. Wherein, activation of the AMP‐

apoptosis.127-130 Mitochondrial PKA can phosphorylate Bad on

dependent protein kinase (AMPK) can phosphorylate and stabilize

Ser112, and Ser155 has been shown to alleviate the inhibitory

|

LUCERO et al.

effects of Bad on anti‐apoptotic proteins Bcl‐2 and Bcl‐xL promot‐
131

ing cell survival.
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Concerning the CNS, PKCε phosphorylation has been shown to in‐

However, PKA activity had also been linked

crease the activity of endothelin converting enzyme (ECE), which

to apoptosis through the phosphorylation and stabilization of Bim

is responsible for amyloid beta clearance, via an N‐terminal mod‐

on Ser83,130 and PKA phosphorylation of Bax on Ser60 promotes

ification site.152 This would indicate that PKCε may be downregu‐

132

As with protein

lated in Alzheimer's disease,153 and restoring PKCε activity could

import, cell context and the dose/duration of signaling should be

be neuroprotective similar to how PKCε activity is observed in car‐

considered when evaluating local outcomes of mitochondrial PKA

diac tissue.

Bax translocation to mitochondria and MOMP.

signaling.
Given the reliance of mitochondria on local PKA signaling, it is
not surprising to find that perturbations in PKA signaling can be
found in neurodegenerative disorders typified by mitochondrial

5 | PA R K I N S O N ' S D I S E A S E R E LE VA NT
PROTE I N K I N A S E S

dysfunction.133-136 In preclinical models of PD, there is diminished
PKA signaling that coincides with data collected in postmortem

Protein kinases have been implicated in the pathogenesis of

brains. Increasing the levels of mitochondrial PKA either through

Parkinson's disease (PD), and discrete changes in protein kinase

increasing AKAP‐1, targeting PKA to mitochondria, or pharma‐

activity have been noted for cytosolic kinases like PKA and JNK

cological activation of PKA can offset mitochondrial dysfunction

that promoted disease physiology (described above). However,

and neuronal cell death in PD models, in particular, those with

two kinases in particular are linked to familial and idiopathic cases

PINK1 deficiency.

96,97,99,104

Similar to PD, dysregulation of PKA

of PD and have populations present on the OMM. Mutants of

signaling has been noted in AD and models with elevated amyloid

the leucine‐rich repeat kinase 2 (LRRK2) and the PTEN‐induc‐

beta.93 Defects in mitochondrial health and trafficking in AD‐like

ible kinase 1 (PINK1) can profoundly impact organelle physiology

conditions were alleviated by the reintroduction of PKA.93,135

contributing to PD pathogenesis and progression. (summarized in

These results indicate that diminished PKA signaling is a com‐

Figure 4).

ponent of neurodegenerative disorders and restoring local PKA
activity could be a means to impede the pathogenesis of these
conditions.

5.1 | Leucine‐rich repeat kinase 2 (LRRK2)
A protein kinase implicated in familial and sporadic cases of PD is
leucine‐rich repeat kinase 2 (LRRK2), wherein mutations in LRRK2

4.2 | Protein kinase C (PKC)

have been shown to increase kinase activity.154 LRRK2 and mutant

Protein kinase C isoforms are emerging as potential regulators of mi‐
137-139

tochondrial function in the areas of metabolism and apoptosis

LRRK2 localize to intracellular membranes in the rodent brain and

;

human cells. Intriguingly, approximately 10% of LRRK2 has been

however, a complicating factor could be that distinct activities of

shown to localize to the OMM,155 and there is increasing evidence

PKC isoform could have discrete impacts on mitochondrial physiol‐

for mutant LRRK2 to directly impact mitochondrial physiology and

ogy. To date, three isoforms of PKC, PKCα,140 PKCδ, and PKCε,141

apoptotic machinery (reviewed in 156). Also, mutant LRRK2‐induced

have shown mitochondrial localization. PKCδ is associated more

mitochondrial dysfunction has been noted in numerous experimen‐

with neurodegeneration and neuroinflammation,142,143 while PKCε

tal models and PD patients.

has been demonstrated to be more protective.144

Increased LRRK2 kinase activity has been linked to the phosphor‐

PKCδ has been shown to undergo cleavage by caspase activity

ylation of and interactions with mitochondrial proteins implicated in

in response to stress, and the cleaved species of PKCδ contributes

organelle dysfunction in PD157 including the uncoupling proteins in

to stress‐induced mitochondrial dysfunction. PKCδ‐induced mito‐

neurons,158 Bcl‐2 proteins,159 Drp‐1,160-163 Miro,164 the mitochon‐

chondrial dysfunction is also associated with dopaminergic neuro‐

drial calcium uniporter (MCU),165 and peroxiredoxin 3 (PRDX3).166

143,145

toxicity in preclinical PD models.

Although the outcomes of

Early studies found that expression of the most common clinical

mitochondrial PKCδ signaling affect apoptosis, respiration, mem‐

LRRK2 mutant G2019S could impact mitochondrial morphology in‐

brane potential, ROS production, antioxidant capacity, and organelle

creasing mitochondrial fission. The enhanced fission was found to

dynamics,146-148 only Drp‐1 has been shown to interact with PKCδ

be a result of interaction between LRRK2:G2019S and Drp‐1.160 The

149

and contribute to organelle fragmentation.

Further investigation

is needed to elaborate on PKCδ functions at mitochondria.

recruitment of Drp‐1 to mitochondrial and subsequent fission in PD
patient‐derived fibroblasts and human SH‐SY5Y cells was found to

PKCε also demonstrates mitochondrial localization in re‐

be dependent upon LRRK2 kinase activity.161,162 Given the recent

sponse to cerebral ischemia and increases sirtuin 5 (Sirt5) levels.150

identification of Rab GTPases, specifically Rab7,167 as bonafide

Outside of this report, most of the work has been performed in

LRRK2 substrates,168 it is likely that mutant LRRK2 activity could

non‐CNS tissues. PKCε has been shown to phosphorylate complex

drive mitochondrial fragmentation observed in PD patients by as‐

IV and increase its activity in the heart and kidney in response to

sembling the protein machinery and activating membrane fusion.169

stress.138,151 Also, PKCε has been shown to phosphorylate and reg‐

LRRK2: G2019S expression in HeLa cells revealed that LRRK2

ulate cardiac sodium channels in response to metabolic changes.

mutants interacted with and phosphorylated Bcl‐2 on Thr56 to
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F I G U R E 4 Parkinson's disease‐related protein kinases impact mitochondrial physiology. PD is associated with mitochondrial dysfunction,
and numerous proteins implicated in familial PD or disease pathogenesis exhibit mitochondrial localization or influence organelle physiology.
(A) Loss‐of‐function mutations in PINK1 are found in familial PD patients. PINK1 accumulates at the OMM following mitochondrial
depolarization leading to its activation by autophosphorylation. An activated PINK1 can then phosphorylation ubiquitin on Ser65 (Ub—
orange circles) and activate/recruit Parkin to stress, aged, or damaged mitochondrial to facilitate their elimination by mitophagy. (B)
Mutations in LRRK2 increase kinase activity and occur in both familial and sporadic PD cases. Increased LRRK2 activity can be linked to
changes in autophagic flux through the manipulation of Bcl‐2 and inhibition of Miro, whereby LRRK2 can interact with and sequester Miro
preventing turnover and trafficking of damaged organelles. LRRK2 mutants, such as G2019S, are also associated with changes in Ca2+
homeostasis through perturbation of mitochondrial calcium uniporter (MCU) and decreased oxidative stress tolerance by phosphorylation‐
dependent impairment of PRDX3. LRRK2 variants are found to affect bioenergetics by inhibiting complex I (not shown) and increasing UCP
abundance and stability. The kinases represent direct effectors of PD‐induced mitochondrial dysfunction

increase autophagy and mitochondrial mass.159 However, Hsieh

because UCP inhibitors exacerbate LRRK2 mutant pathology158

and colleagues reported that LRRK2 in iPSC‐derived neurons facili‐

and overexpression of UCP2 protects against PD‐relevant neuro‐

tate the interaction of damaged mitochondria with the microtubule

toxins, such as MPTP.158 Thus, UCPs may protect by diminishing the

motor accessory protein Miro paving the way for clearance of de‐

production of ROS by aberrant ETC function and compensate for

polarized organelles; consequently, LRRK2:G2019S impedes the in‐

diminished organelle antioxidant capacity. A recent study demon‐

teraction of Miro with damaged mitochondria slowing the clearance

strates that mutant LRRK2 can influence the MCU increasing in‐

164

Additionally,

traorganellar Ca2+ concentrations.165 This elevation in Ca2+ may

LRRK2:G2019S is linked to aberrant mitochondrial trafficking, spe‐

induce ROS production in LRRK2 mutant cells. These studies col‐

cifically axonal transport, through inhibition of the Miro‐mitochon‐

lectively demonstrate that LRRK2 is a crucial component of mito‐

drial interaction.164 Fibroblasts from PD patients do exhibit more

chondrial regulation.

of potentially detrimental organelles from neurons.

mitochondrial fragmentation and enhanced mitophagy initially com‐
pared to control cells. Thus, the role of LRRK2 in mitophagy will re‐
quire a closer examination.169

5.2 | PTEN‐induced kinase 1 (PINK1)

Lastly, enhanced LRRK2 kinase activity can affect ROS levels

PTEN‐induced putative kinase 1 (PINK1) has drawn significant at‐

and production through manipulation of mitochondrial substrates.

tention due to its role in mitophagy and association with PD. Under

While LRRK2 mutants are known to alter ETC function, LRRK2

basal conditions, PINK1 is transported into the mitochondrial ma‐

mutants have been found to alter antioxidant capabilities in mito‐

trix through the translocases of the outer membrane, TOM20 and

chondria. For example, LRRK2:G2019S was found to phosphorylate

TOM23, the translocation channel TOM40, and the translocase of

and impair PRDX3 in drosophila brains diminishing organelle oxi‐

inner membrane TIM23. Inside the mitochondrial matrix, PINK1 is

dant handling capacity.166 Alternatively, patient‐derived fibroblasts

cleaved by a mitochondrial processing peptidase (MPP) and a rhom‐

and SH‐SY5Y cells expressing LRRK2:G2019 have elevated levels

boid protease, PARL.170-172 The cleaved PINK1 is then re‐transported

of uncoupling protein expression, namely UCP2 and UCP4, respec‐

into the cytosol and degraded by the ubiquitin (Ub) proteasome sys‐

158

tively.

Further, the increased expression of UCPs linked to kinase

tem (UPS).171

activity, as the elevation in UCP mRNA was reversed by LRRK2

When PINK1 transport through TOM is hindered, for instance

inhibitors. The increase in UCP appears to be neuroprotective

by a depolarized mitochondria membrane potential (MMP), it

|

LUCERO et al.

accumulates on the OMM and auto‐phosphorylates at Ser228
173,174

and Ser402.

The activated PINK1 phosphorylates Ub chains

847

in the cell cycle have also emerged as OMM signaling agents. The
appearance of these kinases on the OMM is further evidence of the

at Ser65,175,176 which recruit Parkin to the OMM177 and activate

extensive integration of organelle and cell physiologies and quality

Parkin's E3 Ub ligase activity via phosphorylation.178 Just as PINK1

control.

phosphorylates Ub, PINK1 also phosphorylates Parkin directly at
Ser65,179 signifying a secondary mode of Parkin activation.180,181
The phosphorylated Parkin translocates to the mitochondria and is

6.1 | AMP‐dependent protein kinase (AMPK)

further activated by the PINK1‐phosphorylated Ub.177 Parkin's sub‐

A recent addition to the OMM signaling landscape is the AMP‐

sequent ubiquitination of OMM substrates leads to an enrichment of

dependent protein kinase (AMPK), which was identified in two

Ub molecules around the damaged mitochondria that enter a posi‐

independent reports.120,189 First, Toyama and colleagues

182

tive feedback cycle through PINK1 phosphorylation.

189

dem‐

onstrated that AMPK's response to ETC stress (rotenone or anti‐

PINK1 can also alter OMM signal transduction to drive fission.

mycin treatment) leads to the activation of AMPK and ultimately

Activation of PINK1 destabilizes the interaction between PKA and

the colocalization with TOMM20. This study also revealed that mi‐

178

tochondrial fission factor (MFF) was phosphorylated by AMPK on

anchoring protein AKAP‐1, preventing unnecessary mitophagy.

The dissociation of PKA from AKAP‐1 prevents phosphorylation

Ser172, which was required along with Ser155 phosphorylation for

and inhibition of Drp‐1 leading to increased fission. Alternatively,

the recruitment of Drp1 and ultimately stress‐induced mitochon‐

PKA can translocate intracellularly and phosphorylates the mito‐

drial fragmentation.189 Moreover, phosphorylation of Mff on Ser172

chondrial membrane protein MIC60 on Ser528, preventing PINK1

and Ser155 was found to be essential to the proper distribution of

accumulation on the OMM and reducing Parkin recruitment to mi‐

dendritic mitochondria in mouse primary cortical neurons.189 This

tochondria.105 In the presence of mitochondrial pathology, PINK1

study was important because it placed AMPK in proximity to ATP

likely drives reduced mito‐PKA and AKAP, allowing PINK1 to flag

production and provided a mechanistic link between mitochondrial

the damaged mitochondria for degradation through this feedback

bioenergetics and dynamics.
Alternatively, Hoffman et al120 utilized phosphoproteomics to

mechanism.
Accumulation of mitochondrial mutations is observed in the sub‐

identify substrates of AMPK in continuous cell cultures and mus‐

stantia nigra dopaminergic (DA) neurons of PD patients that, due to

cles. One of the validated substrates was an OMM scaffold for

their high metabolic needs, may result in neuronal death. As most

PKA, AKAP‐1. AMPK phosphorylation of AKAP‐1 on Ser103 leads

mutations associated with PINK1 are in the kinase domain,183,184 the

to increased respiration in rat L6 myoblasts likely in a PKA‐de‐

adenosine triphosphate (ATP) analogy kinetin triphosphate (KTP)

pendent manner.120 As mentioned earlier, enhanced mitochondrial

can be used to interact with PINK1, allowing for kinase activity

PKA activity is linked to the improved import of ETC components

and Parkin‐induced mitophagy independent of the mutated kinase

and phosphorylation of ETC enzymes by PKA improves activity.

domain.185 Huntington's disease (HD) can be characterized by the

Therefore, AMPK activity on the OMM is a means to facilitate

presence of ring‐shaped neuronal mitochondria which are formed

ETC activity by sustaining PKA activity through manipulation of

in the presence of reduced mitophagy.186 Overexpressing PINK1

the scaffold AKAP‐1. These studies demonstrate that AMPK is

in HD models reduces the formation of the spheroid mitochondria,

an essential integrator of bioenergetic status190,191 and organelle

decreases the number of damaged mitochondrial, and counteracts

dynamics192 on the mitochondrial surface, and AMPK activity on

187

neurotoxicity.

In Alzheimer's disease (AD), ectopic expression of

PINK1 may be capable of reducing or even preventing, the amyloid‐β

mitochondria may be a player in CNS disorders such as PD193and
ALS.194

(Aβ) plaques that characterize the neurological disease as an accu‐
mulation of dysfunctional mitochondria and oxidative damage have
been shown to precede the Aβ in AD.188 Thus, diminished PINK1

6.2 | Cyclin‐dependent kinase 1 (Cdk1)

activity could be a basal component of neurodegenerative disease

Cyclin‐dependent kinase 1 (Cdk1) complexed with cyclin B is

pathogeneses.

known to impact mitochondrial substrates during mitosis. Cdk1
was first reported to impact mitochondrial proteins in 2007 when
Taguchi and colleagues discovered that Cdk1/cyclin B could phos‐

6 | OTH E R K I N A S E S A S S O C I ATE D W ITH
OMM

chondrial fission prior to cell division.195 It was later demonstrated

As mentioned earlier, the occurrences of cytosolic protein kinases

components of respiratory complex I. The phospho‐manipulation

are increasing and more OMM kinases are being found through

of the complex I subunits ultimately promoted the respiration nec‐

disease‐specific proteomic studies. These include protein kinases

essary to produce the bioenergetic currency necessary for cell

that are implicated in cellular homeostasis, such as AMP‐depend‐

division.196 Both the regulation of mitochondrial fission and res‐

phorylate Drp‐1 on Ser585 (Ser616 human) and promoting mito‐
that Cdk1/cyclin B could impact matrix proteins as well including

ent protein kinase (AMPK), casein kinases (CK1 and CK2), and mam‐

piratory chain by Cdk1/cyclin B have been linked to oncogenesis

malian target of rapamycin (mTOR). Intriguingly, kinases implicated

and therapeutic resistance in brain tumors as well as other types

848
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of cancer.197 Collectively, mitochondrial signaling by Cdk1/cyclin

(ie, Wnt pathway) and circadian rhythms. However, CK1 and CK2

B is an excellent example of the extensive coordination between

have been implicated in the regulation of mitochondrial function.

mitochondrial and cellular programming.

CK1 is involved the inhibition of Fas‐mediated apoptosis through the
phosphorylation of Bid on Ser64 and Ser66. 207,208 Phosphorylation

6.3 | Cyclin‐dependent kinase 5 (Cdk5)
Another example of a Cdk exhibiting OMM signaling capabilities

by CK1 prevents the cleavage of Bid by caspase 8 limiting the re‐
lease of cytochrome c from mitochondria. 207,208 While specific CK1
targets on mitochondria have yet to be identified, CK1 has been

is cyclin‐dependent kinase 5 (Cdk5). Like Cdk1, Cdk5 can phos‐

colocalized with mitochondria, and further studies may unearth CK1

phorylate Drp1 on Ser616 in mature rat neurons, the same site

substrates on mitochondria.

as Cdk1 in mitotic cells, inhibiting mitochondrial fission.198 Cdk5
activity was associated with elongated mitochondria during the
maturation of cultured cortical neurons.198 Intriguingly, Cdk5‐me‐
diated phosphorylation of Drp1 is linked to oncogenic potential in

6.6 | Casein kinase II (CK2)
The role of CK2 on mitochondria is more extensive than CK1

brain tumor initiating cells, in which enhanced Drp1 activity cor‐

where in addition to apoptosis CK2 plays a significant role in

related with a poor glioblastoma prognosis.199 In another study,

the regulation of organelle protein import122,123 and quality con‐

Cdk5 was crucial to N‐methyl‐D‐aspartate (NMDA)‐induced neu‐

trol. 206 Concerning apoptosis, CK2 is known to phosphorylate

ron loss, and elimination of Drp1 phosphorylation or the catalytic

Bcl‐2 proteins and affect their activities. An example includes,

activity of Cdk5 was sufficient to prevent NMDA‐induced cell

like CK1, CK2 can phosphorylate Bid preventing the induction of

death. 200 Furthermore, cerebral granule cells derived from Cdk5‐/‐

apoptosis, activation of caspases, and sustaining the levels mito‐

mice were resistant to NMDA‐induced cytotoxicity compared to

chondrial Bcl‐2. 207 Recent data suggest CK2 has a more promi‐

controls.

200

Cdk5 phosphorylation of Drp1 also occurs in models

nent role in the regulation of mitochondrial protein import. CK2

of neurodegenerative disorders. Cdk5‐mediated phosphorylation

has been associated with the phosphorylation of OMM protein

of Drp1 can promote fission and apoptosis in striatal neurons that

transport components TOM22 and TOM70.122-125 In both cases,

express mutant Huntington, an event that can be exacerbated by

CK2 enhances the localization and function of these transport

the addition of dopamine. 201 This study implicates Cdk5‐Drp1 ac‐

proteins in the OMM and thus positively impacts protein transit

tivation as a component of Huntington disease. Additionally, Cdk5

into mitochondria. Additionally, CK2 phosphorylation of Mim1

phosphorylation of Drp1 occurs in mouse primary cortical neurons

complex stabilizes the protein in the OMM and leads to increased

exposed to amyloid beta (Aβ1‐42). 202 Neurons treated with Aβ1‐42

activity including the incorporation of TOM22 into the OMM and

exhibited increased fission and apoptosis that could be ablated by

TOM super‐complex.122-125 CK2 is implicated in mitophagy as

impairing Cdk5, which may indicate that Cdk5 activation of Drp1

well. 206,209,210 CK2 phosphorylation of OMM mitophagy receptor

Intriguingly, these re‐

FUN14 domain containing 1 (FUNDC1)211 on Ser13 prevents the

ports place a cell cycle enzyme in stress response pathways within

interaction of mitochondria with LC3 reducing mitophagy perhaps

postmitotic cells.

as a means to retain healthy mitochondria. 210 Therefore, CK2 has

may be involved in AD pathophysiology.

202

emerged as a crucial element of mitochondrial physiology and de‐

6.4 | Cyclin‐dependent kinase 11 (Cdk11)

fects in CK2 function could adversely affect organelle physiology
and related human conditions.

Similar to Cdk5, cyclin‐dependent kinase 11 (Cdk11) has been
shown by colocalization studies to have subpopulation on mito‐
chondria. 203,204 After the identification of Cdk11 on mitochon‐

6.7 | Mammalian target of rapamycin (mTOR)

dria, there have been no follow‐up studies to identify substrates.

The mTOR signaling pathway has long been implicated in sensing mi‐

Intriguing the localization of Cdk11 preceded the induction of ap‐

tochondrial substrates like branched amino acids; moreover, mTOR

optosis leading investigators to surmise that Cdk11 may have a role

has been linked to bioenergetics and mitochondrial protein synthesis

in the induction of cell death. 203,204 Cdk11 represents an interesting

for some time. 212,213 The localization of mTOR signaling components

OMM kinase for study, as research related to mitochondria. Cdk11

on lysosomes and in proximity to mitochondrial‐associated mem‐

could shed light on the relationship between organelle physiology

branes (MAMs) meant it was only a matter of time before mitochon‐

and the cell cycle.

drial mTOR substrates would be discovered. 214 Indeed, mTOR was
reported to localize to mitochondria via the OMM protein FKBP38,

6.5 | Casein kinase I (CK1)

a member of the FK506‐binding protein family. 215 This interaction
places mTOR in close to Bcl‐2 proteins associated with VDAC1. 213,216

Both casein kinase I and II (CK1 and CK2) have been described to

Bcl‐2 proteins associated with VDAC1 influence substrate entry into

have mitochondrial influence and localization.124,205,206 CK1 and

mitochondria and dictate the cellular reliance on glycolysis. A recent

CK2 are commonly viewed as Ser/Thr kinases that influence the ac‐

report demonstrates that mitochondrial mTOR can phosphorylate

tivity of transcription factors to influence developmental signaling

Bcl‐xL on Ser62 and this increased cellular reliance on glycolysis in

|
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leukemia cells. 213 The localization of mTOR places the kinase near

phosphatase affects other MAPKs on mitochondria or has unique

other regulators including AMPK making mTOR an emerging regula‐

substrates on the OMM.

tor of mitochondria function capable of responding to changes in
redox status and bioenergetics shifts. Alternatively, mTOR may have
a role in OMM signaling through interplay with AKAP‐1, wherein

7.2 | Phosphate and tensin homolog‐long (PTEN‐L)

mitochondrial PKA signaling may influence mTOR activity. 217 It is

A recent report by Wang et al introduced the presence of the long

clear that mTOR signaling is highly integrated with mitochondria

PTEN isoform, PTEN‐L, on the OMM. 229 Ectopic expression of

physiology.

212,218,219

PTEN‐L impaired mitophagy by preventing Parkin translocation and
reducing the levels of phosphorylated ubiquitin on the mitochondrial
surface. Ablation of PTEN‐L expression promoted mitophagy sug‐

6.8 | P21‐activated kinase 5 (PAK5)

gesting that PTEN‐L could be a negative regulator of PINK1‐depend‐

The p21‐activated kinase 5 (PAK5) is a Ser/Thr protein kinase that

ent mitophagy. 229 Intriguingly, site‐directed mutagenesis to impair

primarily regulates cytoskeleton dynamics and contributes to cell

the lipid phosphatase activity of PTEN‐L did not impact its role in

proliferation.

220

PAK5 exhibits Rho‐kinase‐dependent mitochon‐

drial localization.

221,222

PAK5 was shown to phosphorylate Bad

on Ser112 and prevent Bad migration to mitochondria. 223 This in‐

the control of mitophagy. 229 This study indicates that PTEN‐L has a
unique conformation that permits protein phosphatase activity on
the OMM.

creases levels of Bcl‐2 and prevents apoptosis. 223 Further investi‐
gation is warranted to determine whether PAK5 can phosphorylate
other BH3‐only proteins and whether these modifications coincide
with changes in cytoskeletal dynamics.

7.3 | Protein phosphatase 1 (PP1)
The PP1 is linked to the regulation of local signaling transduction on

The number of reported protein kinases localizing to mitochon‐

the OMM and the function of proteins related to apoptosis. 230-233

dria continues to grow at an increasing pace. The reports of new

PP1 forms a complex with PKA and AKAP1 on the mitochondrial

signaling kinases on the OMM reflect the structural and functional

surface, 234 and in the absence of PKA, PP1 can destabilize AKAP1

integration of mitochondria with other subcellular compartments.

leading to its degradation and reduce potential sites for mitochon‐

Thus, the kinases presented above may only be a modest sampling

drial PKA signaling. 235 This event was linked to the induction of

of the cascades present on the mitochondrial surface.

long‐term depression through the dephosphorylation of AMPA re‐
ceptor. 234 OMM PP1 has been cited as a regulator of p38 signaling

7 | O M M PROTE I N PH OS PH ATA S E S

on mitochondria as well. PKC was found to induce PP1 following
exposure to phorbol ester leading to dephosphorylation and in‐
activation of p38 on the mitochondria. 231 These studies indicate

Compared to the breadth of studies on OMM protein kinases, far

that PP1 could modulate OMM signaling in a context‐dependent

less is known regarding the activities and substrates of protein phos‐

fashion.

phatases on the mitochondrial surface. Because a number of the

PP1 is associated with the dephosphorylation of Bcl‐2 proteins

phosphorylation events ascribed to protein kinases on the OMM

and the induction of apoptosis.232 PP1 dephosphorylation of Bad can

are reversible, it is likely that some phosphatases would be required

release the protein from 14‐3‐3 and permits Bad's interaction with

to offset and regulation these phosphorylation events to adjust and

and inhibition of anti‐apoptotic Bcl‐2 proteins.128 PP1 interaction with

maintain organelle physiology.8,11 We will describe the actions of

Bcl‐2 and Bcl‐xL can also impact phosphatase activity.236 These results

some of the known protein phosphatases on mitochondria below.

indicate PP1 on the OMM is a regulator of apoptotic proteins.

7.1 | Mitogen‐activated protein kinase
phosphatase‐1 (MKP‐1)

7.4 | Protein phosphatase 2A (PP2A)
Similar to PP1, PP2A has been shown to have mitochondrial locali‐

MKP‐1 is a dual specificity phosphatase capable of dephospho‐

zation to the OMM, where it can influence the activities of Bcl‐2

rylating Ser/Thr and Tyr residues modified by protein kinases. 224

proteins and Bad by dephosphorylation. 237,238 However, a distinc‐

As the name implies, the primary substrates of MKP‐1 are the

tion between PP1 and PP2A substrates appears to be the ability of

MAPKs. As described earlier, MAPKs (namely JNK, ERK1/2, and

PP2A to dephosphorylate Drp‐1 and activate the protein. PP2A was

p38) can translocate to mitochondria and manipulate local pro‐

shown to modify Ser656, the same residue phosphorylated by PKA,

teins. MKP‐1 was also found to migrate to neuronal mitochondria

and undo PKA‐mediated inhibition of Drp‐1 leading to mitochondrial

in response to treatment of cells with neuronal growth fac‐

fragmentation and depolarization.95 In neurons, PP2A activation of

tor. 224,225 It is proposed that JNK is a substrate of MKP‐1 on mi‐

Drp‐1 led to decrease synapse formation and shorter and fewer den‐

suggesting that

drites.95 Excessive PP2A activity could be a player in neurological

MKP‐1 may act to inactivation JNK signaling to prevent apopto‐

conditions that may have fragmented mitochondrial networks, such

sis. Further investigation is warranted to determine whether the

as PD.

tochondria based on brain‐related studies

226-228
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crucial to regulating stress responses and preserving optimal orga‐

7.5 | Protein tyrosine phosphatase, non‐receptor
type 11 (PTP1D)

nelle function in the brain.
A recent report indicates that mitochondria AKAPs are ar‐

PTP1D is another phosphatase that has been associated with AKAP1

ranged into specialized membrane microdomains and this physical

on the OMM. 239 PTP1D in response to EGF signaling can dephos‐

interaction places PKA proximal to mitochondrial substrates such

phorylate Src activating its kinase activity. Increased Src activity is

as Bad.248 These microdomain associations are greatly influenced

associated with increased ETC activity by direct phosphorylation of

by local phosphatases capable of influencing the stability of PKA

subunits by Src. 239 In such, PTP1D may act to supplement PKA sign‐

signaling on the OMM. Recently, post‐translational modification of

aling through a shared molecular interaction with AKAP1.

AKAP‐1 has been shown to affect protein stability on the OMM as

Given the diversity of signaling molecules present on the mi‐

well. Dephosphorylation of AKAP‐1 can lead to its ubiquitination

tochondrial surface and the multitude of physical and functional

by E3‐ubiquitin ligase seven in absentia 2 (Siah2) resulting in its

interfaces of the OMM, it is likely that the number of protein phos‐

degradation.244 This ultimately diminishes PKA concentrations on

phatases will increase to regulate the growing populations of protein

mitochondria, which can impair the beneficial effects of local PKA

kinases on the cell surface. Further investigation into the dynamic

signaling. 244 Given the anomalies related to PKA signaling in neu‐

assembly and disassembly of OMM signaling cascades may reveal

rodegenerative disorders, it is likely that disorientation and desta‐

the identity of new OMM phosphatases or new substrates for exist‐

bilization of AKAP‐1 on the OMM could be responsible for the lack

ing OMM phosphatases.

of mitochondrial health in conditions such as AD and PD. Restoring
optimal levels of mitochondrial PKA signaling could help restore or‐
ganelle function and reduce the detrimental effects of mitochondrial

8 | O M M S C A FFO LD PROTE I N S

perturbations in neurodegenerative disease.

Scaffold proteins and adaptor proteins are crucial accessory pro‐
teins required for the coordination of signal transduction events

8.2 | Sab (SH3‐binding protein 5; SH3BP5)

across space and time. 240,241 The relative abundance of accessory

As mentioned above, Sab is an OMM scaffold for the JNK and a pu‐

proteins can dictate the biological outcomes of signaling events by

tative substrate of p38γ on the OMM. 27,28 To date, no other outer

influencing the spatial magnitude and duration of a response. 240,241

membrane kinases have been shown to interact with Sab. This

Therefore, the identification and concentrations of these elements

could be due to the topology of Sab, which may make it selective

of molecular architecture will be critical to determine the presence

for MAPKs on the OMM. Near the C terminus of Sab, there are

and impact of signaling pathways on mitochondria.

two kinase interacting motifs (KIM1 and KIM2) (see Figure 2). The
Sab KIM1 motif is immediately followed by a transmembrane motif,
which would indicate that KIM2 is the only kinase interacting motif

8.1 | A‐kinase anchoring protein 1 (AKAP‐1)

on the cytosolic side of the OMM. Previous studies have indicated

AKAPs are membrane‐bound scaffolds for PKA and its related sign‐
91

that JNK interacts with Sab through the KIM1 motif, while the KIM2

AKAP‐1 can exhibit mitochondrial localization

motif was dispensable for JNK‐mediated phosphorylation. 29,55 A

(often referred to as D‐AKAP1), and reports have placed it on and

study by Win et al29 demonstrating the topology of Sab indicates

aling components.

within mitochondria.

242

Of note, the mitochondrial variants of the

that JNK is on the cytosolic face of the OMM and likely interacting

Akap1 gene most often associated with the OMM are sAKAP‐84,

with KIM2 of Sab. A recent study from our laboratory indicates that

AKAP‐121, and AKAP‐149.

242

Single nucleotide polymorphisms in

JNK phosphorylates Sab on Ser421 which is near KIM2 indicating

Akap1 can alter the subcellular distribution of AKAP1 variants and

that KIM2 is likely the binding site for JNK on the OMM.32 Selective

alter the outcomes of cAMP/PKA signaling. 243 Indeed, the relative

inhibition of the JNK‐Sab interaction reveals that KIMs are neces‐

levels of AKAP1 on the mitochondria can influence the outcomes of

sary for JNK signaling on the mitochondria and JNK‐related mito‐

local PKA signaling.95,96,244-247 By merely increasing AKAP‐1 concen‐

chondrial activities. 26,31-33,54,249,250 The concentrations of Sab on the

trations on mitochondria, investigators have been able to leverage

OMM dictate the outcomes of mitochondrial JNK signaling.31,32,250

the prominent concentrations of PKA in the cytosol to influence mi‐

Recent studies from our laboratory demonstrate that increasing Sab

tochondrial health. Overexpression of AKAP‐1 can protect neurons

levels in mitochondria renders cells vulnerable to stresses due to

and neuron‐like cells against PD relevant neurotoxins and PINK1

elevated levels of JNK signaling on the OMM. Demonstrating that

deficiency as noted earlier. Furthermore, genetic ablation of AKAP1

the relative levels on scaffold proteins on the OMM dictate signaling

was found to exacerbate stroke‐related injury in mice.100 The dele‐

outcomes, and the collective levels of distinct scaffolds could indi‐

tion of Akap1 in mice reduced phosphorylation of Drp‐1 on Ser637,

cate how mitochondria may respond to cellular cues and stresses.

100

which impaired fission.

‐/‐

Reduced Drp1 phosphorylation in Akap1

We have found that Sab mRNA and protein levels are significantly

mice contributed to Ca2+ dysregulation, dysregulation of complex II,

enriched in the hippocampus, substantia nigra, and cerebellum,

and increased ROS production in response to excitotoxic stress.100

areas of the brain vulnerable to neurotoxin stimuli. 251 Thus, we

This suggests that the PKA/AKAP1 mitochondrial signaling nexus is

contend that the elevated Sab concentrations could lead to robust

|
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mitochondrial JNK activity contributing to apoptosis and neurode‐

851

mechanisms (ie, autophagy). But, one can anticipate that the scaf‐

generation in disorders such as AD and PD. Selective disruption of

folding and organization of these molecular pathways will be crit‐

the JNK‐Sab interaction protects dopaminergic neurons from 6‐hy‐

ical to this integration. This potential has been noted with AKAP1,

droxydopamine‐induced neurotoxicity.33 Thus, the specific target‐

which plays a crucial role in the integration of PKA and mTOR sig‐

ing of detrimental mitochondrial JNK signaling could be a promising

naling modules. 217 It is likely that similar mechanisms exist for other

target to preserve mitochondrial health in PD.

signaling proteins to balance mitochondrial form and function in an
everchanging cellular environment. Research oriented around these

8.3 | Protein interacting with C‐kinase‐1 (PICK1)

distinct interactions will be critical to understanding the complex
regulation of mitochondrial function and dysfunction in disease

PICK1 is a scaffold protein for PKCs, and PICK1 has been linked

pathogenesis, and this scenario also highlights the need to consider

to PKAα localization on mitochondria, where the kinase protected

therapeutic regimens that impair detrimental events while restoring

against apoptosis induced by genotoxic stress. 252-254 Another report

beneficial signaling pathways on the OMM.

indicates that PICK1 on mitochondria can impair Parkin activity and

It is likely that the OMM signaling pathways will be highly re‐

contribute to MPTP‐induced neurotoxicity. PICK1 destabilized the

sponsive to mitochondrial messengers, such as ROS, and OMM

interaction between Parkin and UbcH7 leading to diminished E3

proteins are appropriately positioned to recognize and response

ubiquitin ligase activity of Parkin. PICK1 knockout mice were pro‐

to these small molecules. The response to these messengers will

tected against MPTP‐induced cell death. 255 This effect of PICK1 is

shape cellular responses to the organelle health status. An exam‐

interesting in light of the neurotoxic and neuroinflammatory activi‐

ple of this type of integration may be best illustrated by the inter‐

ties of PKCδ and may be another mechanism by which shifts in OMM

play between ROS and the members of the Bcl‐2 superfamily that

signaling can contribute to PD pathogenesis and progression. 256

dictate apoptotic responses. 263 For example, Bcl‐2 can “sense” the

Additional scaffold proteins may also be localized to the OMM, as

magnitude of ROS production in response to post‐translational

reports indicate that 14‐3‐3 may have a population of mitochondrial

modifications, namely Ser70 phosphorylation, 264 and changes in

proteins that influence organelle signaling.

257,258

Also, the growth

Bcl‐2 can then impact ETC function, mitochondrial antioxidant

factor receptor‐bound protein 10 (Grb10) may have OMM localiza‐

capacity, and autophagic flux. 263 The robustness of the Bcl‐2 re‐

tion.

259

We contend that the accurate and reliable identification of

sponse to ROS levels can determine whether a cell undergoes

OMM scaffold proteins will be crucial to determining the localization

apoptosis. Our work demonstrates that enhancing mitochondrial

and signaling pathways to the mitochondrial surface.

JNK signaling by increasing Sab levels amplifies ROS production
and renders cells sensitive to chemical insults in part by diminishing

9 | CO N C LU D I N G R E M A R K S A N D FU T U R E
D I R EC TI O N S

OMM Bcl‐2 levels. 31,32,250 It is established that mitochondrial ROS
can trigger ASK‐1 to engage sustained JNK activity265 leading to
depletion of OMM Bcl‐2 by Ser70 phosphorylation and induction of
apoptosis. 26 In addition to JNK, numerous OMM localized kinases

In this review, we have presented some of the emerging signaling

and phosphatases can modulate Bcl‐2 superfamily protein function,

cascades and phosphorylation events on the mitochondria surface.

which we contend is one significant route to coordinating organelle

OMM signaling components are appropriately positioned to impact

and cellular physiology because of the importance of Bcl‐2 proteins

specific aspects of mitochondrial physiology. It is likely that more rig‐

to metabolism, autophagy, and apoptosis. The actions of OMM sig‐

orous studies in this area will unearth more kinases, phosphatases,

naling proteins in response to ROS could dictate the actions of Bcl‐2

and adaptor proteins. Great care should be taken in identification

proteins within the cell. Thus, it is imperative that OMM signaling

and validation of new signaling components on the OMM using es‐

pathways converging on Bcl‐2 proteins be considered with great re‐

tablished as well as modern proteomic‐based approaches.

spect toward cellular environment.

While the identification of OMM signaling components and

In conclusion, the signalosomes of the OMM are the gatekeepers

signaling cascades continues to be of interest, many of the OMM

of mitochondrial physiology and mediators of disease pathogenesis

kinases are beginning to demonstrate interplay on the organelle sur‐

in the CNS, as such there is much promise in the elucidation of sig‐

face. Earlier, we mentioned that AMPK could stabilize PKA signaling

naling relationships on the mitochondrial surface and targeting dis‐

on mitochondria to enhance ETC function.120 However, antagonism

tinct OMM signaling components to combat CNS disorders.

by kinases may also occur. The best current evidence for this is that
PINK1 can impair the kinase activity of LRRK2, 260-262 an effect
which is lost in iPSC‐derived neurons from PD patients harboring
PINK1 mutations. Similarly, overexpression of Parkin can prevent
dopaminergic neuron loss in the presence of LRRK2:G2019S.
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